Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatic arterial infusion chemotherapy + tyrosine kinase inhibitor
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intra-arterial, Oral
01
Overview
This combination therapy involves the administration of Hepatic Arterial Infusion Chemotherapy (HAIC) using the FOLFOX regimen (oxaliplatin, leucovorin, and fluorouracil) in conjunction with an oral tyrosine kinase inhibitor (TKI), specifically lenvatinib or regorafenib. Developed by Fudan University, this regimen is being evaluated as a second-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have failed first-line therapy. HAIC delivers high concentrations of chemotherapeutic agents directly to the liver tumor via the hepatic artery, minimizing systemic toxicity, while the TKI provides systemic anti-angiogenic and anti-proliferative effects by targeting various receptor tyrosine kinases.
- Other names
- HAIC + TKIHAIC-TKIFOLFOX-HAIC + TKI
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)TEK (Tie2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on hepatic arterial infusion chemotherapy + tyrosine kinase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatic arterial infusion chemotherapy + tyrosine kinase inhibitor.